Putting Science to Work

In the News

  • /Media/Default/images/infd.jpg
    Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

    Money Control-24/01/2018. With a focus on future business growth, the company has done lot of investments – building new infrastructure and capabilities and they are now ready, said Hunt...


  • We are in the process of implementing a $200 million growth capex plan to expand capacity and extend capabilities

    Globally, we anticipate to see a healthy demand for high quality scientific services, not just in the pharma and biotechnology industries but also in other research focused industries...


  • Bristol-Myers Squibb, Syngene International Expand Ongoing Research Collaboration

    Outook-14/11/2017. Syngene will set up a new dedicated facility spread across 25,000 sq. ft. of laboratory and office space for Bristol-Myers Squibb...


  • Expect good momentum to continue in H2FY18: Syngene CEO

    Money Control-26/10/2017. The revenues for Syngene in the second quarter (July-September) were up 10.6 percent at Rs 334.2 crore versus Rs 303 crore for the...


  • Syngene expands Amgen collaboration as it recovers from fire incident

    Outsourcing Pharma-31/07/2017. Syngene International is doubling the footprint of its research and development center....

  • Company on a path of recovery; Q1 has been solid: Manoj Nerurkar, Syngene International

    Economic Times-28/07/2017. Clearly we are on a recovery path, we believe we made a significant progress going from minus 6% to plus 6% in terms of revenue growth ...

  • Aim to get back to around 20% revenue growth in FY18: Syngene

    Money Control-28/04/2017. The tie-up with the Canadia Company is a good start for the biologics business...

  • Initiator Pharma selects Syngene and Research Toxicology Centre (RTC) as primary partners for the preclinical development of IPED2015.

    Cision News-19/04/2017. Initiator Pharma has selected Syngene, India and Research Toxicology Centre, Italy ( RTC) as contract research organizations (CROs) to conduct the pre-clinical development of the drug candidate IPED2015 for the treatment of ED.

  • Biologics and Biosimilars -Promising field for medicines for the future by Dr. Dhananjay Patankar (Head-Pharmaceutical and Biopharmaceutical Development)

    Pharma Focus Asia-09/03/2017. As per Make in India campaign by the government, Indian biotech industry, comprising bio pharmaceuticals, is expected to grow at a rate of 30 per cent a year and reach US$100 billion by 2025.

  • Syngene to co-develop nutrition products for Herbalife

    Business Standard-02/03/2017. It is Syngene's fifth dedicated facility and second for nutrition research, the lab is a testimony of its capabilities to deliver innovative solutions in wide industry segments.

Discovery Chemistry Discovery Biology Safety Assessment Large Molecule Development Chemical Development Formulation Development Stability Studies Polymer Research Integrated Discovery & Development Clinical Development Services Bioinfomatics Antibody Drug Conjugates Oligonucleotide Synthesis Contact Us

This site is best viewed in Firefox (29+), Chrome (35+), or Microsoft Internet Explorer (9+)

Social Widget